Treatment effects of xuebijing injection in severe septic patients with disseminated intravascular coagulation.

Qin Yin,Chunsheng Li

doi:10.1155/2014/949254

Abstract

The treatment effects of Xuebijing (XBJ) injection in severe septic patients with disseminated intravascular coagulation (DIC) were investigated in this study. 171 severe septic patients with DIC were divided into the control group (n = 83) or intervention group (n = 88). Routine therapies were administered in both groups, and XBJ injection was administered additionally in the intervention group. Incidence of DIC, clinical severity scores, and coagulation parameters at 7 days after administration of XBJ injection were compared between the two groups, and short-term prognosis was evaluated by 28-day mortality. Compared with the control group, incidence of DIC in the intervention group was significantly lower at 7 days after administration of XBJ injection (P < 0.001). In addition, differences of platelet count and prothrombin time were significantly greater in the intervention group than in the control group (P all <0.05), and similar results were also found for differences of the Mortality in Emergency Department Sepsis score and Acute Physiology and Chronic Health Evaluation II score (P all <0.05). Furthermore, 28-day mortality was significantly lower in the intervention group (P = 0.034). These results demonstrate that XBJ injection can effectively treat DIC caused by severe sepsis and improve short-term prognosis of severe septic patients with DIC.

Highlights

Despite advancements in modern antibiotics and supportive therapies, the mortality of severe sepsis remains high
The main purpose of this study was to investigate the treatment effects of XBJ injection on Disseminated intravascular coagulation (DIC) caused by severe sepsis
The main findings of this study were as follows: (1) compared with the control group, incidence of DIC was significantly lower in the intervention group at 7 days after administration of XBJ injection; and (2) 28-day mortality was significantly lower in the intervention group than in the control group

Summary

Introduction

Despite advancements in modern antibiotics and supportive therapies, the mortality of severe sepsis remains high. Heparin is the most widely used anticoagulant in clinical practice, but controlled trials did not confirm the survival benefit of heparin [5, 6] Another anticoagulant, recombinant human activated protein C (rhAPC), was reported to decrease mortality in the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study [7], and post hoc data analysis demonstrated that patients with DIC may have a survival benefit in particular [8]. Recombinant human activated protein C (rhAPC), was reported to decrease mortality in the Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study [7], and post hoc data analysis demonstrated that patients with DIC may have a survival benefit in particular [8] This drug was found not to offer a survival benefit in the recent PROWESS-SHOCK study [9]. There is an urgent need for new effective therapies for DIC

Objectives

Methods

Results

Conclusion